Repository logo
 

Beta amyloid deposition maps onto hippocampal and subiculum atrophy in dementia with Lewy bodies.

Accepted version
Peer-reviewed

No Thumbnail Available

Type

Article

Change log

Authors

Donaghy, Paul C 
McKiernan, Elizabeth 
Firbank, Michael J 
Lloyd, Jim 

Abstract

Although dementia with Lewy bodies (DLB) is a synucleinopathy, it is frequently accompanied by beta amyloid (Aβ) accumulation. Elucidating the relationships of Aβ with gray matter atrophy in DLB may yield insights regarding the contributions of comorbid Alzheimer's disease to its disease progression. Twenty healthy controls and 25 DLB subjects underwent clinical assessment, [18F]-Florbetapir, and 3T magnetic resonance imaging. FreeSurfer was used to estimate cortical thickness and subcortical volumes, and PetSurfer was used to quantify [18F]-Florbetapir standardized uptake value ratio. Principal component analysis was used to identify the dominant Aβ component for correlations with regional cortical thickness, hippocampal subfields, and subcortical structures. Relative to healthy controls, the DLB group demonstrated increased Aβ in widespread regions encompassing the frontal and temporoparietal cortices, whereas cortical thinning was restricted to the temporal lobe. Among DLB subjects, the Aβ component was significantly associated with more severe hippocampal and subiculum atrophy. These findings may reflect an early process of superimposed AD-like atrophy in DLB, thereby conferring support for the therapeutic potential of anti-Aβ interventions in people with DLB.

Description

Keywords

Alzheimer's disease, Amyloid, Dementia with Lewy bodies, MRI, PET, Aged, Aged, 80 and over, Alzheimer Disease, Amyloid beta-Peptides, Atrophy, Disease Progression, Female, Hippocampus, Humans, Lewy Body Disease, Magnetic Resonance Imaging, Male, Middle Aged, Positron-Emission Tomography

Journal Title

Neurobiol Aging

Conference Name

Journal ISSN

0197-4580
1558-1497

Volume Title

73

Publisher

Elsevier BV
Sponsorship
NIHR Newcastle Biomedical Research Centre; Eli Lilly and Company